创模生物科技(北京)有限公司

CN / En

NEWS

InnoModels Biotechnology: What are the features of the in vivo tumor platform?

  • Categories:Company news
  • Author:InnoModels Biotechnology
  • Origin:InnoModels Biotechnology
  • Time of issue:2024-01-25 14:18
  • Views:

(Summary description)The In Vivo Tumor Experimental Platform from InnoModels Biotechnology is an advanced research technology designed to provide a reliable and efficient tool for cancer research and drug development. The following are some of the distinguishing features of the platform

InnoModels Biotechnology: What are the features of the in vivo tumor platform?

(Summary description)The In Vivo Tumor Experimental Platform from InnoModels Biotechnology is an advanced research technology designed to provide a reliable and efficient tool for cancer research and drug development. The following are some of the distinguishing features of the platform

  • Categories:Company news
  • Author:InnoModels Biotechnology
  • Origin:InnoModels Biotechnology
  • Time of issue:2024-01-25 14:18
  • Views:
Information

The In Vivo Tumor Experimental Platform from InnoModels Biotechnology is an advanced research technology designed to provide a reliable and efficient tool for cancer research and drug development. The following are some of the distinguishing features of the platform:
1. In vivo environment simulation: The platform is able to simulate the real environment of tumor development in living animals. This enables researchers to more accurately study key processes such as tumor growth, spread, invasion and treatment response.
2. Abundant Tumor Types: The platform supports many different types of tumor models, including transplanted tumor models, in situ tumor models, and so on. This diversity enables researchers to choose the tumor type that best suits their research objectives.
3. Personalized Experiment Design: InnoModels Biotechnology provides researchers with the service of personalized experiment design, adjusting the specific parameters of the tumor model according to their research needs to ensure the flexibility and controllability of the experiments.

 


4. Tumor Treatment Effectiveness Evaluation: The platform can be used to evaluate the effectiveness of various tumor treatments, including drug therapies, immunotherapies, and so on. Researchers can comprehensively assess treatment effects by monitoring indicators such as tumor growth, volume and metabolism.
5. High visualization and real-time monitoring: The experimental platform features high visualization, allowing researchers to monitor tumor growth and treatment effects in real time. This helps to adjust the experimental program in time and obtain more accurate research data.
6. Strict quality control: InnoModels Biotechnology conducts strict quality control on the in vivo tumor platform to ensure the reproducibility of each experiment and the reliability of the results. This is crucial to the validity of scientific research.
7. Customized Service: InnoModels Biotechnology provides customized service to adjust the characteristics of tumor models according to the specific needs of researchers in order to meet the individual requirements of different research projects.
By providing this advanced in vivo oncology platform, InnoModels Biotechnology provides scientists in the field of cancer research and treatment with a powerful tool that is expected to accelerate the process of new drug discovery and contribute to innovation in the field of cancer treatment. The application of this technology will contribute to a deeper understanding of tumor biology and provide strong support for the development of personalized therapeutic approaches.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司